Cellebrite DI Ltd. (CLBT) Stock Price & How to Invest

Cellebrite DI Ltd. sells the digital-intelligence toolchain used in criminal investigations. Its access products (the Inseyets line, successor to the UFED hardware kits) unlock and extract data from mobile devices, Guardian handles cloud-based evidence review and sharing across agencies, Pathfinder and the newer AI products correlate evidence across seized devices, and Endpoint Inspector covers computers and corporate endpoints. Customers are police forces, national security agencies, prosecutors and, increasingly, corporate investigations and incident-response teams. The company is headquartered in Petah Tikva, Israel, listed on Nasdaq after a 2021 SPAC merger, and files as a foreign private issuer on Form 20-F. In late 2025 it closed the ~$170 million acquisition of Corellium, whose virtualized ARM device platform is used for mobile app security research, and paired that deal with a restructuring.

The investment picture is a subscription software story wearing a government-contracting jacket. Annual recurring revenue reached ~$493 million in Q1 2026, up ~21% year over year, on ~$128 million of quarterly revenue (~$118 million of it subscription) at an ~86% gross margin, with ~$31 million of adjusted EBITDA and a trailing free cash flow margin near ~32%. The balance sheet held ~$535 million in cash and investments with no meaningful debt, so at a ~$3.9 billion market value the enterprise trades near ~7x trailing revenue. What that multiple pays for is renewal-heavy demand from agencies that rarely switch vendors; what it exposes is lumpy public-sector purchasing, an ongoing arms race against Apple and Google device security, and the reputational risk of tools sold to states that misuse them.

Revenue depends on government budgets, so procurement freezes, continuing resolutions and election-cycle delays can push deals across quarters with no change in demand. Access capability is a moving target: every iOS and Android hardening release can strip a supported extraction method, and Cellebrite must keep re-earning it, which is why its spring 2026 update advertising iPhone 17 and iOS 26 support was itself news. The reputational exposure is real and recurring, from Amnesty International's 2024 report on Cellebrite tools used against Serbian activists (after which the company stopped selling there) to political scrutiny of its expanded U.S. immigration-enforcement contracts. Competition is well capitalized, with Magnet Forensics and GrayKey combined under private ownership. As an Israel-domiciled foreign private issuer, Cellebrite reports on a 20-F with semiannual rather than quarterly filing obligations, carries regional geopolitical risk, and its GAAP results swing on warrant revaluation and share-based compensation.

7 analysts publish price targets on CLBT, averaging $21.29 against a $16.01 price as of August 2026, or +33.0%. The published targets run from $15.00 to $28.00, a moderate spread, and the ratings split 7 buy, 0 hold, 0 sell. Over the last six months there has been 1 raise and 2 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full CLBT forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Cellebrite DI Ltd.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. ARR compounding on the subscription shift. Cellebrite finished Q1 2026 with ~$493 million of ARR, up ~21%, and guided Q2 ARR to ~$510 million to ~$513 million with net new ARR of ~$17 million to ~$20 million. The most optimistic published target, $28.00, assumes this works close to its best case.

The case against. Revenue depends on government budgets, so procurement freezes, continuing resolutions and election-cycle delays can push deals across quarters with no change in demand. The most pessimistic target, $15.00, is roughly what CLBT is worth if this bites instead.

Read the full bull and bear case on CLBT, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Cellebrite DI Ltd.'s investor relations page or your broker.

• Revenue (TTM): ~$496 million
• ARR (Q1 2026): ~$493 million, up ~21% year over year
• Q1 2026 revenue and adjusted EBITDA: ~$128 million revenue, ~$31 million adjusted EBITDA, ~86% gross margin
• FY2026 revenue guidance: ~$565 million to ~$571 million
• Market capitalization: ~$3.9 billion (~$16 per share, mid-July 2026)
• Cash and investments: ~$535 million, no meaningful debt, so roughly ~7x trailing revenue on enterprise value

Q1 2026, reported May 14, met or beat the high end of guidance on both ARR and revenue, and full-year guidance was reaffirmed rather than raised. GAAP net income was ~$30.6 million (~$0.12 diluted), though GAAP figures move with warrant and stock-compensation accounting, so the company steers on ARR and adjusted EBITDA. Second-quarter 2026 results are scheduled for August 13, 2026, and the number under the most scrutiny is net new ARR, which the guidance implies grows about ~50% sequentially at the midpoint.

Other names that sit close to CLBT: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get CLBT exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so CLBT sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where CLBT fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Cellebrite is a high-margin, cash-generative software franchise in digital investigations, priced for continued 20% ARR growth in a business whose customers are governments and whose headlines are frequently uncomfortable.

Whether CLBT is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is CLBT a buy or a sell?, and where the stock could go from here in the CLBT stock forecast.

For income investors, whether CLBT pays a dividend and how the payout looks is covered in does CLBT pay a dividend? And to weigh CLBT against a peer, read the full side-by-side comparisons: CLBT vs MSI and CLBT vs PLTR.